DGX

Quest Diagnostics Incorporated

HealthcareDiagnostics & ResearchNASDAQ

$194.90

+$1.09 (0.56%)today

Conviction

7/ 10

Fair Value$217.88

Upside+11.79%

Signal8.25

Market Cap$21.4B

52W Range$160.02–$213.50

Next EarningsApr 21

Conviction History

Conviction Changes

No conviction changes recorded

Premium Content

Upgrade to premium to see the full reasoning behind each conviction change.

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$207.24

Current Price$195.51

Upside / Down+6.0%

P(Undervalued)61.1%

P(20%+ Up)27.6%

P(15%+ Down)15.6%

Fair Value Distribution — percentile bands

61.1% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

4.6%/yr

±4.0% · revenue growth to justify current price

FCF-Based Reverse DCF

4.7%/yr

±3.2% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kMar 4

Conviction: unchanged

FY2025 10-K Deep Read: Thesis Intact, Valuation Full Near-Term

Quest FY2025 confirms defensive compounder thesis. $11B revenue stable, Advanced Dx $1B+ growing double-digits. FDA LDT rule vacated (favorable), PAMA delayed to 2026. 15th dividend increase. Stock ne...

sec_10kMar 3

Conviction: unchanged

FY2025 Performance: Strong Core Business, Advanced Diagnostics Growth Outpacing Headwinds

Quest reported stable FY2025 with Advanced Diagnostics and operational efficiency offsetting reimbursement headwinds. Strong market position, B+ Advanced Dx revenue on double-digit growth, AI/automati...